Document is current
Any future updates will be listed below
-
Authors
Gavin, Patrick G
Allman, Erik L
Jayne, David https://orcid.org/0000-0002-1712-0637
Mysler, Eduardo
Amoura, Zahir
Di Poto, Cristina
Tian, Xiang
Hess, Sonja
Csomor, Eszter
Brohawn, Philip Z
Muthas, Daniel
Platt, Adam
Anzillotti, Consuelo
Stone, Heena
Seth, Asha
Woollard, Kevin
Al-Mossawi, Hussein
Lindholm, Catharina
Ferrari, Nicola
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02547922 at ClinicalTrials.govnct02547922 at ClinicalTrials.govDocuments that mention this clinical trial
Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial
https://doi.org/10.1136/rmdopen-2025-005932
POS0409 IMPROVEMENTS IN CD163, A URINARY BIOMARKER OF RENAL INFLAMMATION, WITH ANIFROLUMAB: RESULTS FROM A PHASE 2 TRIAL IN LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2024-eular.1292
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
https://doi.org/10.1136/annrheumdis-2021-221478
POS0690 RANDOMIZED, CONTROLLED, PHASE 2 TRIAL OF TYPE 1 IFN INHIBITOR ANIFROLUMAB IN PATIENTS WITH ACTIVE PROLIFERATIVE LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.1605
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
https://doi.org/10.1136/lupus-2023-000910
OP0136 METABOLOMIC SERUM PROFILING IDENTIFIES METABOLITES LINKED TO KIDNEY DAMAGE WHICH ARE MODULATED BY ANIFROLUMAB IN A PHASE 2 TRIAL IN LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.1569
POS0739 THE RENAL ACTIVITY INDEX FOR LUPUS (RAIL) DIFFERENTIATES ACTIVE AND INACTIVE NEPHRITIS IN ADULT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
https://doi.org/10.1136/annrheumdis-2022-eular.1654
PO.5.97 The renal activity index for lupus (RAIL) identifies active renal disease in SLE patients and its longitudinal score associates with renal responses in lupus nephritis
https://doi.org/10.1136/lupus-2022-elm2022.122
Collagen Remodeling Biomarkers in Lupus Nephritis
https://doi.org/10.34067/kid.0004732021
nct05138133 at ClinicalTrials.govDocuments that mention this clinical trial
Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial
https://doi.org/10.1136/rmdopen-2025-005932
POS0409 IMPROVEMENTS IN CD163, A URINARY BIOMARKER OF RENAL INFLAMMATION, WITH ANIFROLUMAB: RESULTS FROM A PHASE 2 TRIAL IN LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2024-eular.1292
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
https://doi.org/10.1136/annrheumdis-2021-221478
POS0690 RANDOMIZED, CONTROLLED, PHASE 2 TRIAL OF TYPE 1 IFN INHIBITOR ANIFROLUMAB IN PATIENTS WITH ACTIVE PROLIFERATIVE LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.1605
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
https://doi.org/10.1136/lupus-2023-000910
OP0136 METABOLOMIC SERUM PROFILING IDENTIFIES METABOLITES LINKED TO KIDNEY DAMAGE WHICH ARE MODULATED BY ANIFROLUMAB IN A PHASE 2 TRIAL IN LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.1569
POS0739 THE RENAL ACTIVITY INDEX FOR LUPUS (RAIL) DIFFERENTIATES ACTIVE AND INACTIVE NEPHRITIS IN ADULT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
https://doi.org/10.1136/annrheumdis-2022-eular.1654
PO.5.97 The renal activity index for lupus (RAIL) identifies active renal disease in SLE patients and its longitudinal score associates with renal responses in lupus nephritis
https://doi.org/10.1136/lupus-2022-elm2022.122
Collagen Remodeling Biomarkers in Lupus Nephritis
https://doi.org/10.34067/kid.0004732021
Documents that mention this clinical trial
Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial
https://doi.org/10.1136/rmdopen-2025-005932
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
https://doi.org/10.1136/lupus-2023-000910
Advances in the management of chronic kidney disease
https://doi.org/10.1136/bmj-2022-074216
-
Funding
Funding for this research was provided by:
AstraZeneca (N/A)
- License Information
